Interesting post-hoc analyses of autoimmune ILDs from INBUILD trial presented at #ACR2019 by Dr. Matteson:
The numbers get small when stratified by especific ILDs but the central tendencies of effect suggest that RAILD and SSc-ILD might derive similar benefit from nintedanib. 1/

This somewhat different from the effect size seen on SENSCIS trial (nintedanib for SSc-ILD). So hypothesis:
- pts on INBUILD trial were not allowed additional immunosuppression (and immunosuppression does work for SSc-ILD)
- Somewhat different pop recruited?
@sclerodermaUM 2/

Finally, when stratifying by UIP vs. other fibrotic patterns, the central tendencies suggest that the greatest benefit of nintedanib might be among the most fibrotic lesions, and that makes me wonder that there might be different dz molecular pathways playing out 3/3

(in my mind: Let's not lump different stuff together)